Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Real-world brain imaging by EEG requires accurate annotation of complex subject-environment interactions in event-rich tasks and paradigms. This paper describes the evolution of the Hierarchical Event Descriptor (HED) system for systematically describing both laboratory and real-world events. HED version 2, first described here, provides the semantic capability of describing a variety of subject and environmental states. HED descriptions can include stimulus presentation events on screen or in virtual worlds, experimental or spontaneous events occurring in the real world environment, and events experienced via one or multiple sensory modalities. Furthermore, HED 2 can distinguish between the mere presence of an object and its actual (or putative) perception by a subject. Although the HED framework has implicit ontological and linked data representations, the user-interface for HED annotation is more intuitive than traditional ontological annotation. We believe that hiding the formal representations allows for a more user-friendly interface, making consistent, detailed tagging of experimental, and real-world events possible for research users. HED is extensible while retaining the advantages of having an enforced common core vocabulary. We have developed a collection of tools to support HED tag assignment and validation; these are available at hedtags.org. A plug-in for EEGLAB (sccn.ucsd.edu/eeglab), CTAGGER, is also available to speed the process of tagging existing studies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065975PMC
http://dx.doi.org/10.3389/fninf.2016.00042DOI Listing

Publication Analysis

Top Keywords

real-world events
12
hierarchical event
8
events
6
event descriptors
4
descriptors semi-structured
4
semi-structured tagging
4
real-world
4
tagging real-world
4
events large-scale
4
large-scale eeg
4

Similar Publications

Introduction: Etripamil is a fast-acting intranasally self-administered calcium-channel blocker developed for termination of paroxysmal supraventricular tachycardia (PSVT). Prior studies have demonstrated safety and efficacy of etripamil for PSVT termination following an initial medically supervised test dose during sinus rhythm. NODE-303 is an open-label, single-arm study that evaluated etripamil for multiple, at-home PSVT episodes, without test dose before first use.

View Article and Find Full Text PDF

Background: Well-differentiated (WDLPS) and dedifferentiated liposarcomas (DDLPS) are subtypes with distinct behaviors, often driven by CDK4 amplification. While CDK4/6 inhibitors such as palbociclib show promise in trials, real-world data are scarce.

Methods: We retrospectively analyzed 21 patients with advanced WDLPS or DDLPS treated with palbociclib monotherapy at 16 Turkish Oncology Group centers (2019-2022).

View Article and Find Full Text PDF

Background: Tildrakizumab has demonstrated high efficacy and a good long-term safety profile, including low malignancy rates, in Phase III trials with 5-year extension. Despite these data, the real-world evidence on patients with psoriasis and a history of cancer is limited.

Objectives: To assess the efficacy and safety of tildrakizumab in a cohort of patients with moderate-to-severe psoriasis and a previous or current history of neoplasia.

View Article and Find Full Text PDF

Background: Neuropathic pain (NP) is frequently resistant to conventional treatments. Botulinum toxin type A (BT-A) is a recommended option for focal peripheral NP, but the dynamics of its effect in real-life conditions remain poorly characterized.

Objective: To assess BT-A efficacy in a real-world study of patients with focal peripheral NP, over a 1-year follow-up period.

View Article and Find Full Text PDF

Introduction: Injectable extended-release buprenorphine is an effective treatment for opioid use disorder (OUD), but injection site reactions (ISRs) are common treatment-emergent adverse events that may impact patient comfort, adherence, and outcome. This report examines the clinical presentation, prevalence, and management of Sublocade-related ISRs through two case studies and a review of existing literature.

Case Presentation: We present two cases of ISRs in patients receiving extended-release buprenorphine, Sublocade.

View Article and Find Full Text PDF